QNZ (EVP4593), a selective NF-κB inhibitor, selectively kills myeloma cells while sparing healthy counterparts, suppresses tumor growth in vivo, and synergizes with approved myeloma therapies. These findings establish NF-κB inhibition as a promising and combinable therapeutic strategy in multiple myeloma.
